EpiCept Announces Successful Completion Of Enrollment For Phase I Trial Of EPC2407
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced that it has completed its Phase I clinical trial for EPC2407. The trial has met all of its objectives. EPC2407 is EpiCept’s novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. EpiCept successfully identified the maximum tolerated dose of EPC2407 in the Phase I study.
